Here, we show that GO could be used for the treatment of CML-CP as it seems to push CML CD34+ cells into the cell cycle (Figure 3e) and drives CML LSC into differentiation, as suggested by the sequencing results (Figure 5e). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.